AVITA Medical(US:RCEL) Globenewswire·2026-01-13 13:25Core Insights - AVITA Medical, Inc. announced preliminary financial results for Q4 and fiscal year 2025, along with an outlook for fiscal year 2026, highlighting a shift from stabilization to growth execution [1][2] Financial Performance - Total net revenues for Q4 2025 were approximately $17.6 million, a decrease from $18.4 million in Q4 2024 [6] - Total revenues for the full year 2025 were approximately $71.6 million, an increase of about 11% compared to $64.3 million in 2024, aligning with the company's revised revenue guidance [6] - Full year 2026 revenue is expected to be in the range of approximately $80 to $85 million, representing growth of approximately 12% to 19% compared to 2025 [6] Capital Structure and Financing - The company closed a five-year credit facility with Perceptive Advisors, providing up to $60 million in capital, with an initial funding of $50 million [2][4] - The proceeds from the credit facility will be used to repay outstanding debt and support the growth of the acute wound care portfolio [2][4] - The new credit facility includes trailing twelve-month (TTM) revenue covenants, with an initial TTM revenue covenant set at $68.5 million for Q1 2026 and $73 million for the full year 2026 [3] Clinical and Commercial Developments - The Cohealyx-I study is fully enrolled, and the PermeaDerm-I study has surpassed 75% enrollment as of December 2025, with data expected later in 2026 [6] - The company is positioned to leverage its differentiated position in acute wound care for value creation through commercial execution and clinical advancement [4]